Phase I Study Evaluating TXA127 in Low/Intermediate-1 Risk Myelodysplastic Syndrome and Thrombocytopenia
NCT01362036
·
clinicaltrials.gov ↗
PHASE1
Phase
TERMINATED
Status
2
Enrollment
INDUSTRY
Sponsor class
Stopped
Enrollment feasibility issues, new study in design
Conditions
Myelodysplastic Syndrome (MDS)
Interventions
DRUG:
TXA127
Sponsor
Tarix Pharmaceuticals